Healthcare - Press Releases

SUZHOU, China, May 6, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC), key assets in CStone Pipeline 2.0, have been delivered at the 2025 American Association for Cancer Research (AACR) Annual Meeting.

LOS ANGELES, May 6, 2025 /PRNewswire/ --May isALS Awareness Month, and the ALS Network is committed to raising awareness and understanding of the devastating disease that has no known cure. This month, we highlight the power of community and invite everyone to explore the many ways to get involved, give back, and learn more.

TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint research* with RIBOMIC Inc. (President: Yoshikazu Nakamura, Headquarters: Minato-ku, Tokyo, hereinafter referred to as "RIBOMIC"), a drug discovery startup focused on the development and production of aptamer pharmaceuticals, on the development of technology for controlling the pharmacokinetics of nucleic acid aptamers using the antibody-drug conjugate (ADC) manufacturing technology "AJICAP" (hereinafter referred to as "AJICAP"). As a result of this research, RIBOMIC has successfully extended the half-life of a conjugate of nucleic acid aptamers and the Fc region of immunoglobulins in the bloodstream.

TOKYO, May 6, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint research* with RIBOMIC Inc. (President: Yoshikazu Nakamura, Headquarters: Minato-ku, Tokyo, hereinafter referred to as "RIBOMIC"), a drug discovery startup focused on the development and production of aptamer pharmaceuticals, on the development of technology for controlling the pharmacokinetics of nucleic acid aptamers using the antibody-drug conjugate (ADC) manufacturing technology "AJICAP" (hereinafter referred to as "AJICAP"). As a result of this research, RIBOMIC has successfully extended the half-life of a conjugate of nucleic acid aptamers and the Fc region of immunoglobulins in the bloodstream.

BUDAPEST, Hongrie, 7 mai 2025 /PRNewswire/ -- Un centre offrant un soutien mdical et ducatif ainsi qu'un abri aux femmes vulnrables a t construit Bamako, la capitale du Mali, grce l'aide financire de Gedeon Richter. En tant que l'un des principaux fabricants mondiaux de mdicaments pour la sant des femmes, Richter souligne l'importance de promouvoir la sant et la qualit de vie des femmes dans tous les pays o il opre. Avec ce nouveau centre, en mesure d'accueillir des dizaines de femmes dfavorises de la rgion, Richter a pour objectif de venir en aide prs de 300 femmes par an. Cette initiative n'est pas un simple investissement ponctuel, car l'entreprise pharmaceutique s'est engage soutenir long terme le fonctionnement de la Maison de l'Espoir.

BUDAPEST, Hungra, 7 de mayo de 2025 /PRNewswire/ -- En Bamako, capital de Mali, se ha construido un centro que ofrece atencin mdica, apoyo educativo y albergue para mujeres vulnerables, con la ayuda financiera de Gedeon Richter. Como uno de los principales fabricantes mundiales de medicamentos para la salud femenina, Richter enfatiza la importancia de promover la salud y la calidad de vida de las mujeres en todos los pases donde opera. Con el nuevo centro, capaz de albergar a decenas de mujeres desfavorecidas de la regin, Richter aspira a brindar ayuda a casi 300 mujeres al ao. Esta iniciativa no es una inversin puntual, ya que la compaa farmacutica se compromete a apoyar a largo plazo el funcionamiento del centro House of Hope.

SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Caplight Technologies, an innovator in private market data and trading infrastructure, today announced the issuance of a patent by the United States Patent and Trademark Office protecting Caplight's proprietary method for estimating private company stock prices using secondary market transaction data.

Labbit's graph-based architecture supports the unique needs of Grant's different lab environments while unifying data to deliver full traceability for quality assurance and regulatory compliance.

More than half of Aging Life Care Managers' clients are living with dementia, a new national survey finds.

Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary cause of blindness related to diabetes. This marks the second approved indication for Susvimo, which was initially cleared in October 2021 as an alternative to frequent eye injections for wet age-related macular degeneration.

PLAINSBORO, N.J., April 30, 2025 /PRNewswire/ -- Today, The New England Journal of Medicine(NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which investigated the effects of once-weekly subcutaneous semaglutide 2.4 mg on liver histology compared to placebo at 72 weeks in adults with MASH and moderate to advanced liver fibrosis (stage 2 or 3). At Week 72, the first primary endpoint showed 62.9% of people treated with semaglutide 2.4 mg achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% on placebo with estimated difference in responder proportions (EDP) of 28.7% (95% CI, 21.1 to 36.2; P<0.001). For the second primary endpoint at Week 72, 36.8% of people treated with semaglutide 2.4 mg achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% on placebo (EDP, 14.4%; 95% CI, 7.5 to 21.3; P<0.001).1

CALGARY, AB, April 30, 2025 /PRNewswire/ -Willow Biosciences Inc. (the "Company") (TSX:WLLW) (OTCQB: CANSF) announces the completion today of the sale (the "Transaction") of its wholly-owned operating subsidiary, Epimeron USA, Inc., to the U.S. subsidiary of Mycofeast Ltd., a privately-held, arms-length entity based in the United Kingdom (the "Purchaser"), pursuant to the terms of a share purchase agreement dated March 14, 2025 (the "Share Purchase Agreement"), between the Company and the Purchaser.

FREDERICK, Md., April 30, 2025 /PRNewswire/ -- RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease.

YMCA Launches Interactive Teen Mental Health Resource Hub for Mental Health Awareness Month

PALMETTO, Fla., April 30, 2025 /PRNewswire/ -- BayCare, the leading health care system in West Central Florida, broke ground today on BayCare Hospital Manatee, its 17th hospital, and BayCare HealthHub(Manatee). This milestone marks a significant step in expanding access to health care for the growing Manatee County community. The hospital will be the county's first not-for-profit hospital and the only hospital north of the Manatee River.

MEXICO CITY, April 30, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2025. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise mentioned.

DURHAM, N.C., April 30, 2025 /PRNewswire/ --Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi(dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101.

Experten der Pharmaindustrie kommen zusammen, um die Zukunft der KI mitzugestalten

Blue Earth Therapeutics (PRNewsfoto/Blue Earth Therapeutics Ltd)

SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investigational stroke therapy, SNE-101. This is the first exosome-based therapy in Korea to enter clinical trials, marking a major milestone in the country's biopharmaceutical landscape.

The national non-profit organization recognizes how superhero moms like Chelsea Noble Cameron shape generations, recognizing birth moms, adoptive moms and foster moms.

The industry veteran brings over 25 years of healthcare marketing expertise in accelerating growth and value for leading pharmaceutical brands

LAGUNA HILLS, Calif., May 1, 2025 /PRNewswire/ -- MemorialCare Saddleback Medical Centerhas earned an "A" Hospital Safety Grade from The Leapfrog Group, a national nonprofit watchdog that sets rigorous standards for excellence in patient care. This marks the eighth time Saddleback Medical Center has received an "A" grade, recognizing Saddleback Medical Center's achievements in protecting patients from preventable harm and error in the hospital.

AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- OsteoCentric Technologies, a global leader in innovative fastener technologies, announced the creation of seven wholly-owned subsidiaries dedicated to penetrating key industrial market segments including Aerospace & Defense, Transportation, Construction, Oil & Gas, Automotive, Agriculture, and Sporting Goods. This strategic move leverages the company's proprietary UnifiMI Fastener Technology to address some of the most critical challenges, across the most demanding industrial applications.

Para conmemorar cuatro dcadas de innovacin, Systech ofrece una plataforma nica para CDMO que elimina los dolores de cabeza que generan mltiples proveedores y brinda visibilidad, desde la lnea de envasado hasta el cliente.